Neoadjuvant Treatment with Preoperative Radiotherapy for Extremity Soft Tissue Sarcomas: Long-Term Results from a Single Institution in Turkey

被引:4
作者
Dincbas, Fazilet Oner [1 ]
Oksuz, Didem Colpan [1 ]
Yetmen, Ozlem [6 ]
Hiz, Murat [2 ]
Dervisoglu, Sergulen [3 ]
Turna, Hande [4 ]
Kantarci, Fatih [5 ]
Mandel, Nil Molinas [7 ]
Koca, Sedat [8 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Radiat Oncol, Istanbul, Turkey
[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Orthoped Surg, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Pathol, Istanbul, Turkey
[4] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[5] Istanbul Univ, Cerrahpasa Med Fac, Dept Radiol, Istanbul, Turkey
[6] Lutfi Kirdar Kartal Training & Res Hosp, Dept Radiat Oncol, Istanbul, Turkey
[7] VKV Amer Hosp, Dept Med Oncol, Istanbul, Turkey
[8] Bahcesehir Univ, Fac Med, Dept Radiat Oncol, Istanbul, Turkey
关键词
Soft-tissue sarcomas; preoperative radiotherapy/chemotherapy; limb-sparing surgery; RADIATION-THERAPY; POSTOPERATIVE RADIOTHERAPY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; LOCAL-CONTROL; HIGH-GRADE; HIGH-RISK; TRIAL; MORBIDITY; SURGERY;
D O I
10.7314/APJCP.2014.15.4.1775
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To assess the long term clinical outcome of preoperative radiotherapy with or without chemotherapy followed by limb sparing surgery in patients with non-metastatic soft tissue sarcomas (STS) of the extremities. Materials and Methods: Sixty patients with locally advanced STS were retrospectively analyzed. The median tumor diameter was 12 cm. All patients were treated with preoperative radiotherapy delivered with two different fractionation schedules (35Gy/10fr or 46-50Gy/23-25fr). Neoadjuvant chemotherapy was added to 44 patients with large and/or high grade tumors. Surgery was performed 2-6 weeks after radiotherapy. Chemotherapy was completed up to 6 courses after surgery in patients who had good responses. Results: Median follow-up time was 67 months (8-268 months). All of the patients had limb sparing surgery. The 5-year local control (LC), disease free (DFS) and overall survival (OSS) rates for all of the patients were 81%, 48.1% and 68.3% respectively. 5-year LC, DFS and cause specific survival (CSS) were 81.7%, 47%, 69.8%, and 80%, 60%, 60% in the chemoradiotherapy and radiotherapy groups, respectively. On univariate analysis, patients who were treated with hypofractionation experienced significantly superior LC, DFS and CSS rates with similar rates of late toxicity when compared with patients who were treated with conventional fractionation and statistical significance was retained on multivariate analysis. Conclusions: Treatment results are consistent with the literature. As neoadjuvant chemoradiotherapy provides effective LC and CSS with acceptable morbidity, it should be preferred for patients with large and borderline resectable STS.
引用
收藏
页码:1775 / 1781
页数:7
相关论文
共 28 条
  • [1] A Systematic Review and Meta-Analysis of Oncologic Outcomes of Pre- Versus Postoperative Radiation in Localized Resectable Soft-Tissue Sarcoma
    Al-Absi, Emad
    Farrokhyar, Forough
    Sharma, Rajrish
    Whelan, Kaitlyn
    Corbett, Tom
    Patel, Malti
    Ghert, Michelle
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (05) : 1367 - 1374
  • [2] The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity
    Dagan, Roi
    Indelicato, Daniel J.
    McGee, Lisa
    Morris, Christopher G.
    Kirwan, Jessica M.
    Knapik, Jacquelyn
    Reith, John
    Scarborough, Mark T.
    Gibbs, C. Parker
    Marcus, Robert B., Jr.
    Zlotecki, Robert A.
    [J]. CANCER, 2012, 118 (12) : 3199 - 3207
  • [3] Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma
    Davis, AM
    O'Sullivan, B
    Turcotte, R
    Bell, R
    Catton, C
    Chabot, P
    Wunder, J
    Hammond, A
    Benk, V
    Kandel, R
    Goddard, K
    Zee, B
    Day, A
    Tu, DS
    Pater, J
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 75 (01) : 48 - 53
  • [4] Optimizing radiation therapy and post-treatment function in the management of extremity soft tissue sarcoma
    DeLaney T.F.
    [J]. Current Treatment Options in Oncology, 2004, 5 (6) : 463 - 476
  • [5] EILBER FR, 1984, CANCER-AM CANCER SOC, V53, P2579, DOI 10.1002/1097-0142(19840615)53:12<2579::AID-CNCR2820531202>3.0.CO
  • [6] 2-V
  • [7] A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma
    Gortzak, E
    Azzarelli, A
    Buesa, J
    Bramwell, VHC
    van Coevorden, F
    van Geel, AN
    Ezzat, A
    Santoro, A
    Oosterhuis, JW
    van Glabbeke, M
    Kirkpatrick, A
    Verweij, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (09) : 1096 - 1103
  • [8] Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma
    Grobmyer, SR
    Maki, RG
    Demetri, GD
    Mazumdar, M
    Riedel, E
    Brennan, MF
    Singer, S
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (11) : 1667 - 1672
  • [9] IMPROVED SURVIVAL WITH RADIATION THERAPY IN HIGH-GRADE SOFT TISSUE SARCOMAS OF THE EXTREMITIES: A SEER ANALYSIS
    Koshy, Matthew
    Rich, Shayna E.
    Mohiuddin, Majid M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 203 - 209
  • [10] Long-Term Results of a Phase 2 Study of Neoadjuvant Chemotherapy and Radiotherapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall Radiation Therapy Oncology Group Trial 9514
    Kraybill, William G.
    Harris, Jonathan
    Spiro, Ira J.
    Ettinger, David S.
    DeLaney, Thomas F.
    Blum, Ronald H.
    Lucas, David R.
    Harmon, David C.
    Letson, G. Douglas
    Eisenberg, Burton
    [J]. CANCER, 2010, 116 (19) : 4613 - 4621